GlassScriptPhysician profile
Dmitry Michael Arbuck
NPI 1700872033
$40,382.14
in general payments reported to CMS, 2019-2025
59 companies · $2,969 in 2025
The $2,969 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,280 · 2020: $12K · 2021: $16K · 2022: $2,201 · 2023: $2,409 · 2024: $3,167 · 2025: $2,969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,301 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,300.92 |
| Education | $243.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13,955.19 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Allergan, INC. | $10,675.19 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $2,697.71 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biodelivery Sciences International, INC. | $1,600.22 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $1,210.28 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $1,201.98 | 2019-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $896.16 | 2019-2025 | Rexulti, Vyepti |
| Eisai INC. | $490.04 | 2020-2021 | |
| Pfizer INC. | $482.54 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $477.04 | 2020-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $412.20 | 2020-2023 | Belsomra |
| Boston Scientific Corporation | $404.84 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, General - Therapies |
| Amgen INC. | $387.99 | 2019-2024 | Evenity, Prolia |
| Otsuka America Pharmaceutical, INC. | $336.49 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Collegium Pharmaceutical, INC. | $266.74 | 2022-2025 | Belbuca, Xtampza |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitry Arbuck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.